The Preventable team at i3S is happy to have organised the latest IGCLC consensus meeting to define guidelines for genetic testing, management and treatment of HDGC patients. Glad to count with experts from 4 continents around 22 countries and 53 cities, attended by 164 participants ranging from 114 professionals including a founder of CDH1 mutation in Portugal, 33 patients, and 5 patients associations.
The 5th International Gastric Cancer Linkage Consortium (IGCLC) meeting took place in Porto, Portugal from June 13th-15th 2024 chaired b. The meeting brought together healthcare professionals, researchers, and patients from around the world, who have been treating, studying or dealing with Hereditary Diffuse Gastric and Lobular Breast Cancer syndrome (most well-known as Hereditary Diffuse Gastric Cancer or HDGC). Besides defining more accurate guidelines for the diagnosis and management of patients and families at risk, the fifth time meeting was with the major goal of discussing and updating the Consensus Clinical Guidelines for this disease.
Chaired by:
Carla Oliveira and Fátima Carneiro
Organised by:
i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal
IPATIMUP – Institute of Molecular Pathology and Immunology of the University of Porto, Portugal
FMUP – Faculty of Medicine, University of Porto, Portugal
More information about the meeting, visit: https://www.i3s.up.pt/event.php?v=304
